We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Applications for Next-Generation DNA Sequencing to Accelerate Quantification and Library Prep

By LabMedica International staff writers
Posted on 22 Nov 2009
Print article
For scientists looking to perform next-generation DNA sequencing, a new range of tools has been developed that can greatly simplify and accelerate library preparation as well as enabling absolute quantification of amplified sequences.

Next-generation sequencing has the potential to transform life science in fields as diverse as human genomics, species discovery, and personalized medicine--any field in which advancement depends on a deeper understanding of genomic variation and transcriptome complexity. Compared to generation I (Sanger) sequencing of the Human Genome Project, generation II technology lowers the cost per base dramatically while producing giga-base results per day. In spite of this cost-effectiveness, the technology faces barriers to widespread adoption, among them the complexity of sample preparation and quantification, particularly when preparing 100,000,000 or 1,000,000,000 amplicons for deep resequencing.

The Fluidigm (South San Francisco, CA, USA) Access Array integrated fluidic circuit (IFC) eases the burden of library preparation for resequencing or long-range polymerase chain reaction (PCR) because it facilitates the amplification and bar-coding of 48 samples in parallel, with minimal time and labor and in as few as three hours with yields that are equimolar and routinely at 100,000,000 or 1,000,000,000. Because every sample may be identified by its barcode, all 48 samples can be multiplexed at the sequencing step. This capability dramatically reduces the time and money required for large-scale projects, opening new vistas of research. For example, scientists interested in large cohort studies can comparatively easily sequence specific genes of interest from hundreds of individuals in just a matter of weeks.

While simple in theory, next-generation sequencing can be very challenging because of the lack of an easy and effective method to quantify the concentration of molecules within sequencing libraries. The Slingshot kit from Fluidigm is the first product to easily determine the optimal sample concentration-before samples advance to sequencing. With SlingShot, digital PCR is used to easily determine the absolute quantity of target sequences, thereby improving sequencing results generally and enabling the sequencing of previously undetectable samples.

By exploiting the unique microfluidic properties of IFCs to detect only amplifiable molecules within the sample mixture--SlingShot has extremely small sample requirements typically offering a 1,000-fold reduction in input volumes. As IFCs are able to count individual molecules--using digital PCR--SlingShot eliminates titration steps at the sequencing stage. SlingShot is also easy-to-use requiring only three liquid-handling steps per library. The unique power of SlingShot can be used to improve the productivity of next-generation sequencing tools from almost any manufacturer.

Fluidigm develops, manufactures, and markets proprietary IFC systems that considerably improve productivity in life-science research. Fluidigm's IFC enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfluidic device (IFC). Fluidigm's systems, consisting of instrumentation, software, and single-use chips, increase throughput, decrease costs, and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the U.S. Food and Drug Administration for use as a diagnostic and are only available for research use

Related Links:
Fluidigm



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Silver Member
Static Concentrator
BJP 10
New
Automated Nucleic Acid Extractor
eLab

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The AI program analyzes a microscopy image from a tumor biopsy and determines what genes are likely turned on and off in the cells it contains (Photo courtesy of Olivier Gevaert/Stanford Medicine)

AI Tool ‘Sees’ Cancer Gene Signatures in Biopsy Images

To assess the type and severity of cancer, pathologists typically examine thin slices of a tumor biopsy under a microscope. However, to understand the genomic alterations driving the tumor's growth, scientists... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.